Development of high-throughput screening assays for detecting early gastric cancer: translating proteomics research into clinical outcomes using emerging mass spectrometry and photonics technologies

点击翻译按钮获取中文摘要

Gastric cancer (GC) is the second leading cause of cancer death worldwide, claiming the lives of >11,000 Australians from 1996-2006. Individuals diagnosed with GC have an expected 5-year survival rate of 10-30%. This could be improved if cases were identified in the early stages of the disease where treatments are more effective. Researchers from Adelaide and Melbourne are developing a diagnostic assay for early-stage GC based on a novel detection system that requires only a drop of blood.